EYENのチャート
EYENの企業情報
| symbol | EYEN |
|---|---|
| 会社名 | Eyenovia Inc （アイノビア） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | ― 医療関連（Health Care） |
| 概要 | 事業概要 -- アイノビアは米国のバイオ医薬品メ―カ―。主に眼科用医薬品の開発・商業化に注力する。同社の主な候補薬には、慢性閉塞隅角緑内障の治療薬「MicroProst」、散瞳の治療を対象とする「MicroStat」、ドライアイ治療薬の「MicroTears」、近視治療薬「MicroPine」などがある。本社所在地はニューヨーク。 eyenovia, inc. (nasdaq: eyen) is a specialty biopharmaceutical company building a portfolio of next generation topical eye treatments based on its proprietary delivery and formulation platform for microdosing. eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for myopia progression, presbyopia, mydriasis and other eye diseases. |
| 本社所在地 | 501 Fifth Avenue Suite 1404 New York NY 10017 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | ― |
| 設立年月日 | 41699 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2018年 |
| 従業員数 | － |
| url | www.eyenoviabio.com |
| nasdaq_url | https://www.nasdaq.com/symbol/eyen |
| adr_tso | ― |
| EBITDA | EBITDA ー |
| 終値（lastsale） | 3.97 |
| 時価総額（marketcap） | 39694624.62 |
| 時価総額 | 時価総額 ― |
| 売上高 | 売上高 -- |
| 企業価値(EV) | 企業価値(EV) ー |
| 当期純利益 | 当期純利益 -- |
| 決算概要 | 決算概要 -- |
EYENのテクニカル分析
EYENのニュース
Eyenovia, Inc.: Eyenovia Expands Its US Manufacturing Capabilities 2023/06/06 13:02:00 Finanz Nachrichten
Eyenovia is stepping up the capabilities of its facilities and taking advantage of the thriving innovation culture and expertise in Reno, Nevada, and Redwood City, CaliforniaNEW YORK, NY / ACCESSWI…
Eyenovia Expands Its US Manufacturing Capabilities 2023/06/06 13:00:00 Accesswire
Eyenovia is stepping up the capabilities of its facilities and taking advantage of the thriving innovation culture and expertise in Reno, Nevada, and Redwood City, California NEW YORK, NY / ACCESSWIRE / June 6, 2023 / Eyenovia, Inc. (NASDAQ:EYEN), an ophthalmic technology company commercializing and developing the Optejet® device for use both in connection with its own mydriasis product and product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, is proud to announce the expansion of its U.S. manufacturing facilities in Redwood City, California, and Reno, Nevada. The Bay Area is known for its thriving biotech industry , and in Reno, the medical device and technology sectors are booming in part due to having the largest industrial park in the world, which are some of the driving factors behind Eyenovia''s expansion plans. The Redwood City facility, which was announced operational last year, focuses primarily on Optejet® pharmaceutical manufacturing finishing operations, including drug loading, labeling, and packaging prior to distribution.
Eyenovia: Say Goodbye To The Eye Dropper And Welcome Optejet To The Market Place 2023/05/27 07:10:32 Seeking Alpha
FDA gave approval of their first drug on May 8th, 2023. The company is now finalizing its drug launch in the coming months. Click here to read more on EYEN stock.
Eyenovia, Inc. (EYEN) Q1 2023 Earnings Call Transcript 2023/05/12 02:17:06 Seeking Alpha
Eyenovia, Inc. (NASDAQ:NASDAQ:EYEN) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ETCompany ParticipantsJohn Gandolfo - CFO & SecretaryMichael Rowe - CEO & DirectorBren Kern…
Recap: Eyenovia Q1 Earnings 2023/05/11 20:35:19 Benzinga
Eyenovia (NASDAQ: EYEN ) reported its Q1 earnings results on Thursday, May 11, 2023 at 04:05 PM. Here''s what investors need to know about the announcement. Earnings Eyenovia beat estimated earnings by 21.05%, reporting an EPS … Full story available on Benzinga.com
Eyenovia Announces Independent Director Stephen Benjamin to Step Down to Assume Role of Head of White House''s Office of Public Engagement 2023/02/28 21:05:00 Benzinga
NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN ), a pre-commercial ophthalmic technology company developing the Optejet ® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that Stephen Benjamin, an independent director on the Company''s Board of Directors, is stepping down to assume the role of Head of the White House''s Office of Public Engagement. Mr. Benjamin, an attorney, former three-term mayor of Columbia, South Carolina and 76 th President of the U.S. Conference of Mayors, with an extensive record of achievement in government and the public sector, joined the Eyenovia Board in February 2022. "We are beyond thrilled for Stephen, and wish him all the best in this important and high-profile role within the President''s administration," stated Michael Rowe, Chief Executive Officer of Eyenovia. "Over the past year, Steve Benjamin''s insights and guidance have served us well at Eyenovia, and it is due in part to his service that we have achieved so much during that time." Eyenovia''s Board will continue to consist of seven members.
Eyenovia Announces Independent Director Stephen Benjamin to Step Down to Assume Role of Head of White House’s Office of Public Engagement 2023/02/28 21:05:00 GlobeNewswire
NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet ® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that Stephen Benjamin, an independent director on the Company’s Board of Directors, is stepping down to assume the role of Head of the White House’s Office of Public Engagement.
Eyenovia: Countdown To May 8, 2023 (NASDAQ:EYEN) 2023/02/25 08:36:44 Seeking Alpha
I will update my previous two articles about Eyenovia. NDA accepted with no outside advisory committee formed to review their submission. Read more here.
Eyenovia Inc Announces Development Collaboration Agreement with Formosa Pharmaceuticals 2023/02/15 14:53:01 Investing.com
https://www.investing.com/news/assorted/eyenovia-inc-announces-development-collaboration-agreement-with-formosa-pharmaceuticals-432SI-3004274
Eyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals 2023/02/15 14:51:00 GlobeNewswire
Collaboration will combine Eyenovia’s Optejet® dispensing technology with Formosa’s APNT™ nanoparticle formulation platform for the potential development of new topical therapeutics in high-value ophthalmic indications with significant unmet medical needs. Collaboration will combine Eyenovia’s Optejet® dispensing technology with Formosa’s APNT™ nanoparticle formulation platform for the potential development of new topical therapeutics in high-value ophthalmic indications with significant unmet medical needs.
Eyenovia, Inc. (EYEN) CEO Sean Ianchulev on Q4 2021 Results - Earnings Call Transcript 2022/03/29 02:13:03 Seeking Alpha
Eyenovia GAAP EPS of $0.10 beats by $0.32, revenue of $10M 2022/03/28 20:13:09 Seeking Alpha
Eyenovia press release (EYEN): Q4 GAAP EPS of $0.10 beats by $0.32.Revenue of $10M (+400.0% Y/Y).As of December 31, 2021, the Company’s cash and cash equivalents were approximately…
Eyenovia Reports Fourth Quarter and Full Year 2021 Financial Results 2022/03/28 20:05:00 GlobeNewswire
Successfully completed Type A meeting with FDA and anticipates MydCombi™ NDA resubmission in Q3 2022
Eyenovia Raises 15M Via Equity To Advance MydCombi Program 2022/03/04 14:07:56 Benzinga
Eyenovia Inc (NASDAQ: EYEN ) has entered into a Securities Purchase Agreement with Armistice Capital Master Fund Ltd for gross proceeds of $15 million . The offering includes 3 million shares, pre-funded warrants to purchase up to 1.87 million shares, and common warrants to purchase up to 4.87 million shares. The aggregate offering price for each share of … Full story available on Benzinga.com